Recruiting

Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19

This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19. Researchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients…

ClinicalTrials.gov IDNCT06871293
PhaseNA
Enrollment374
SponsorFundación Cardioinfantil Instituto de Cardiología
Age18 Years
SexALL
I'm interested View official listing

Conditions studied

Long COVID-19 Syndrome, COVID 19, Noncommunicable Disease, Hypertension, Diabetes Mellitus, Long COVID

About this study

This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19. Researchers will compare a structured rehabilitation program to informational support through evidence-based messages to determine if rehabilitation leads to better functional and cognitive outcomes in patients with Long Covid-19. Participants will be randomly assigned to one of two groups: 1. Functional and cognitive rehabilitation: Attending weekly in-person sessions for 8 weeks, including supervised physical and cognitive exercises. 2. Informational support: Receiving weekly evidence-based educational messages for 8 weeks. Participants will undergo assessments at baseline, post-intervention, and six months later, including a six-minute walk test, handgrip strength measurement, and questionnaires on disability, anxiety, depression, fatigue, dyspnea, cognitive function, and quality of life.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Covid-19 confirmed. * History of arterial hypertension or diabetes mellitus before entering the institutional registries of the FCI-IC or HOMIL, institutional registries of the FCI-IC or HOMIL or before having the diagnosis of SARSCoV-2 infection. * Persistence of two or more concurrent symptoms, related to Covid-19 prologue, for at least 4 weeks (persistent, intermittent, or intermittent). * At least one of these symptoms must have an impact on activities of daily living. They can be physical (fatigue, dyspnea, myalgias, arthralgias) or neuropsychiatric (cognitive, sleep and emotional alterations). * Symptoms unexplained by underlying disease or other condition concomitant with SARS-CoV-2 infection. SARS-CoV-2 infection (determined by prior medical history review and participant interview). participant interview). \- Ability to read and attend functional and cognitive rehabilitation sessions or to receive the with evidence-based informational messages. Exclusion Criteria: * Age \>80 years. * Severely advanced baseline comorbidities prior to SARS-CoV-2 infection. * Presence of chronic respiratory disease (partial or permanent supplemental oxygen use), cardiac failure (LVEF\<40%) or advanced renal disease (GFR\<30%). heart failure (LVEF\<40%) or advanced renal disease (GFR\<30). * Two hospitalizations in the year prior to admission to the institutional registries of the FCI-IC and the HOMIL for the patient's underlying disease. * Dependence on a caregiver. * Orthopedic or cardiopulmonary problems that contraindicate the performance of aerobic exercise. * Neuropsychiatric or cognitive limitations that limit understanding or following commands and performing attention exercises.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.